Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Leung, Rufina ^a   Proitsi, Petroula ^b   Simmons, Andrew ^a,b   Lunnon, Katie ^b   Güntert, Andreas ^b   Kronenberg, Deborah ^a   Pritchard, Megan ^a   Tsolaki, Magda ^c   Mecocci, Patrizia ^d   Kloszewska, Iwona ^e   Vellas, Bruno ^f   Soininen, Hilkka ^g   Wahlund, Lars Olaf ^h   Lovestone, Simon ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF PERUGIA   (Italy)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; PLATELET DERIVED GROWTH FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; BRAIN ATROPHY; BRAIN REGION; BRAIN SIZE; BRAIN VENTRICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DETERMINATION;

AGED; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; COGNITION DISORDERS; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; INFLAMMATION MEDIATORS; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84878893173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064971     Document Type: Article

References (44)

1. Bailey P, (2007) Biological markers in Alzheimer's disease. Can J Neurol Sci 34Suppl 1: S72-76.
2. Lovestone S, Guntert A, Hye A, Lynham S, Thambisetty M, et al. (2007) Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert Rev Proteomics 4: 227-238.
3. Noelker C, Hampel H, Dodel R, (2011) Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol Diagn Ther 15: 83-102.
4. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ, (2000) Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 21: 39-47.
5. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ, (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6: 295-303.
6. Petrella JR, Coleman RE, Doraiswamy PM, (2003) Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-336.
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J,et al. ((2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
8. Mrak RE, Griffin WS, (2005) Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8: 369-375.
9. Bonifati DM, Kishore U, (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44: 999-1010.
10. Eikelenboom P, Veerhuis R, (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17: 673-680.
11. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D, (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24: 173-182.
12. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL, (1989) A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 48: 674-691.
13. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, et al. (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113: 1685-1695.
14. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC, (2003) Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24: 321-331.
15. Griffin WS, (2006) Inflammation and neurodegenerative diseases. Am J Clin Nutr 83: 470S-474S.
16. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362.
17. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, et al. (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69: 1310-1317.
18. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, et al. (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69: 1318-1325.
19. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, et al. (2009) AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180: 36-46.
20. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, et al. (2009) MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 1180: 47-55.
21. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, et al. (2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27: 685-691.
22. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, et al. (2011) The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 26: 75-82.
23. Jobst KA, Smith AD, Szatmari M, Molyneux A, Esiri ME, et al. (1992) Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340: 1179-1183.
24. O'Brien JT, (2007) Role of imaging techniques in the diagnosis of dementia. Br J Radiol 80 Spec No 2: S71-77.
25. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, et al. (1999) Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 52: 1153-1158.
26. Scheltens P, Fox N, Barkhof F, De Carli C, (2002) Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1: 13-21.
27. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, et al. (1989) On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19: 689-694.
28. Haga S, Ikeda K, Sato M, Ishii T, (1993) Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 601: 88-94.
29. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, et al. (1997) Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 51: 135-138.
30. McGeer PL, Schulzer M, McGeer EG, (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425-432.
31. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, et al. (1999) Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J Neuroimmunol 93: 45-52.
32. Yao J, Keri JE, Taffs RE, Colton CA, (1992) Characterization of interleukin-1 production by microglia in culture. Brain Res 591: 88-93.
33. Suo Z, Tan J, Placzek A, Crawford F, Fang C, et al. (1998) Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807: 110-117.
34. Grammas P, Ovase R, (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 22: 837-842.
35. McGeer PL, McGeer EG, (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21: 195-218.
36. Zhao B, Schwartz JP, (1998) Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res 52: 7-16.
37. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, et al. (2012) Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol: 1-8.
38. Konsman JP, Parnet P, Dantzer R, (2002) Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25: 154-159.
39. Banks WA, Farr SA, Morley JE, (2002) Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 10: 319-327.
40. Perry VH, (2004) The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18: 407-413.
41. Gomez Ravetti M, Moscato P, (2008) Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One 3: e3111.
42. Dziedzic T, (2006) Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen 21: 258-262.
43. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, et al. (2009) Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 163: 55-72.
44. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M, (2009) Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. J Alzheimers Dis 17: 115-123.